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Allele pathogenicityRapid advances and cost erosion in exome and genome analysis of patients with both rare and common genetic
disorders have accelerated gene discovery and illuminated fundamental biological mechanisms. The thrill of dis-
covery has been accompanied, however, with the sobering appreciation that human genomes are burdenedwith
a large number of rare and ultra rare variants, thereby posing a signiﬁcant challenge in dissecting both the effect
of such alleles on protein function and also the biological relevance of these events to patient pathology. In an ef-
fort to developmodel systems that are able to generate surrogates of humanpathologies, a powerful suite of tools
have been developed in zebraﬁsh, taking advantage of the relatively small (compared to invertebrate models)
evolutionary distance of that genome to humans, the orthology of several organs and signaling processes, and
the suitability of this organism for medium and high throughput phenotypic screening. Here we will review
the use of this model organism in dissecting human genetic disorders; we will highlight how diverse strategies
have informed disease causality and genetic architecture; and we will discuss relative strengths and limitations
of these approaches in the context of medical genome sequencing. This article is part of a Special Issue entitled:
From Genome to Function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction: challenges and opportunities from human genetics
Major inﬂections in genomic advances have always been accom-
panied by accelerated discovery of lesions associated with human
pathologies. The development of the ﬁrst karyotype led rapidly to
the discovery of syndromes of polyploidy [1], while the then nascent
technologies of genome mapping, cloning and sequencing yielded
early insights into rare disease pathogenesis [2]. As the ﬁeld progressed,
molecular cytogenetics at the sub-Mb and ultimately kb-level resolu-
tion revealed the high contribution of copy number variants to both
rare and common human genetic disorders [3], while, most recently,
whole exome and whole genome sequencing (WES/WGS) have
hyper-accelerated disease gene discovery both in historical cohorts
and in the real-time clinical setting [4].
Amid the euphoria of discovery and the acutely increased expecta-
tion from patients and their physicians that the application of genomics
can accelerate diagnosis and focus treatment options, the sobering real-
ization has also emerged that each individual human genome is bur-
dened with a large number of rare and ultra rare alleles. Considering
bona ﬁde pathogenic mutations alone in the average human exome,
studies have reported a median of 50–150 nonsense mutations, several
in homozygosity, while the abundance of unique single nucleotidenome to Function.
atsanis@cellbio.duke.eduvariants (SNVs) can be in the low tomid 100s [5]. Importantly, the num-
ber of rare and ultra-rare SNVs has continued to increase proportionate-
ly to the number of available exomes and genomes [6], indicating that
we are unlikely to reach saturation of such alleles soon. These observa-
tions have generated a signiﬁcant interpretive problem for disease gene
discovery and for clinical genomics, as population-based arguments
alone have been unable to dissect the contribution of the majority of
these alleles to clinical phenotypes. Computational algorithms that
take into consideration a variety of evolutionary, structural and bio-
physical properties of proteins have been of some assistance; however,
their predictive ability (estimated in the 70–80% range [7]) has
remained somewhat limited, mandating that deﬁnitive assessment of
pathogenicity must be carried out through other methods.
Animal studies combine the identiﬁcation of candidate alleles for
human diseases with mutant organisms that recapitulate the human
mutation or loss of gene function, and have improved our understand-
ing of the causal link between genetic mutation and phenotypic trait
[8]. Numerous animal models have been developed to study both
monogenic and complex disease. Eachmodel system has its advantages
and limitations, such as genetic and anatomic homology to humans, the
size of the genetic toolkit, generation time, and cost. Here we will focus
on the application of zebraﬁsh in modeling human genetic disease, an
organism that has gained utility by bridging the gap between the
high throughput abilities of invertebrates and the orthology of struc-
ture of mammals (Tables 1, 2). Although not a panacea, the imple-
mentation of zebraﬁsh complementation studies [9] – suppression
of the orthologous zebraﬁsh gene and rescue with either a mutant or
Table 1
General attributes similarities of laboratory organisms used to model human genetic disease.
C. elegans D. melanogaster D. rerio M. musculus
Percent identity with Homo sapiens 43% 61% 70% 80%
Genome size 9.7 × 107 bp 1.3 × 108 bp 1.4 × 109 bp 2.5 × 109 bp
Exome size 28.1 Mb 30.9 Mb 96 Mb 49.6 Mb
Practical attributes
Husbandry demands $ $ $ $$$
Cost per animal $ $ $ $$$
Characterized inbred strains + + + ++++
Outbred laboratory strains + + +++ ++
Germline/embryonic cryopreservation Yes No Yes Yes
Lifespan 2 weeks 0.3 years 2–3 years 1.3–3 years
Generation interval 5.5 days 2 weeks 3 months 6–8 weeks
Number of offspring 300 larva 10–20 eggs N200 embryos/clutch 10–12 pups/litter
Embryonic development ex vivo ex vivo ex vivo in utero
Molecular biology tools
Transgenesis⁎ ++++ +++ ++++ +++
Gene targeting⁎ ++++ +++ + ++++
Conditional gene targeting + ++ + ++++
Transient in vivo assays⁎ +++ ++ ++++ +
Allelic series from TILLING⁎ +++ +++ ++++ ++
Affordability of large scale screens⁎⁎ ++++ ++++ +++ +
Cell biology tools
Cell lines and tissue culture + ++ + ++++
Antibody reagents + ++ + ++++
In situ probes + +++ ++++ +++
Disease process
Birth defects + ++ ++++ ++++
Adult-onset ++ + + ++++
Behavioral ++ ++ ++ ++
Aging +++ ++ ++ ++
Metabolic ++ ++ +++ +++
Table adapted from Lieschke and Currie 2007. Nat Rev Genet. 8: 353–367.
⁎ Reverse genetics.
⁎⁎ Forward genetic.
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medical genomics has facilitated disease gene discovery in both mono-
genic and complex traits, and has also found application in modeling
more intricate (and challenging) genetic lesions that include CNVs
and epistatic interactions. We will review the tools available, discuss
their possible uses and limitations and place the current vector of devel-
opment of this model organism in the context of the ever-expanding
generation of patient genomic data and the need for their accurate
interpretation.1.1. Animal models of human genetic disease
A deep understanding of the genetic architecture of human disease,
underlying cellular andmolecularmechanisms, and the development of
therapeutic paradigms is dependent on model organisms that can ro-
bustly capture the pathology under investigation. Mammalian models
such as themouse (Musmusculus) have historically been attractive plat-
forms by virtue of a high level of genomic sequence homology to
humans (N80%) [10], highly conserved anatomical and physiological
features, and a diverse repertoire of gene targeting strategies to recapit-
ulate human disease phenotypes (for scholarly reviews of this topic see
[11,12]). However, in the context of human genomics, time and cost
now present signiﬁcant drawbacks. By contrast, invertebrate models
such as the nematode worm (Caenorhabditis elegans), or the fruit ﬂy
(Drosophila melanogaster) offer inexpensive alternatives, and have
proven especially powerful for studying orthologous genes of interest
through the use of sophisticated gene manipulation strategies (RNAi,
transposable insertion elements etc.; refs [13,14] for reviews). Nonethe-
less, the reduced cost and increased experimental tractability of these
models are accompanied with a greater disparity in cellular processes
and structures in comparison to humans, in large part due to adecreased percentage of genes shared between species (43% and 61%
for worm and ﬂy versus human, respectively [15]). An intermediate
model, the zebraﬁsh (Danio rerio), has emerged as strong candidate to
achieve the experimental tractability of its invertebrate counterparts,
but with the genomic and physiological proximity of a vertebrate for
the investigation of human genetic disease.2. Zebraﬁsh: an overview
The zebraﬁsh is a tropical teleost that lives in the freshwaters of
south-east Asia. In the late 1960s, George Streisinger transitioned this
common aquarium species to a model for basic research of embryogen-
esis and organ development because of its “desirable attributes,” includ-
ing a relatively short generation time of three to fourmonths, the ability
of mating pairs to generate several hundred embryos that develop rap-
idly and synchronously ex vivo, and the small size of adult ﬁsh (3 cm in
length), making them easy to care for [16]. Moreover, embryos are
transparent, allowing facile microscopic visualization in the ﬁrst days
of development, with major organ formation occurring 24 hours post-
fertilization. Zebraﬁsh have a diploid genome, but differ notably from
the genomic structure of other vertebrates by the major teleost speciﬁc
genome duplication that has resulted in sub-functionalization and neo-
functionalization of genes [17–19]. Importantly, the biomedical re-
search community now has a publicly available, extensively annotated
version of the zebraﬁsh genome at its disposal, of which 70% of genes
have an identiﬁable human ortholog [20]. Additionally, a vast catalog
of mutants, transgenic reporters, and gene-speciﬁc expression data
has been generated from over two decades of dedicated D. rerio use
for “phenotype-driven” forward genetic screens and “gene-driven” re-
verse genetic approaches. These data are curated in ZFIN (the Zebraﬁsh
Model Organism Database), a community-wide resource warehousing
Table 2
Anatomical comparisons between zebraﬁsh and humans.
Anatomy Key similarities Key differences
Embryology • Cleavage, early patterning, gastrulation, somitogenesis, organogenesis are all represented • Rapid
• Inﬂuence of maternal transcripts
• Non-placental, involves hatching
Skeletal system • Ossiﬁed skeleton comprising cartilage and bone • Lack long bone, cancellous bone, and bone marrow
• Joints are not weight-bearing
Muscle • Axial and appendicular muscle groups • Fast- and slow-twitch muscle topographically separate
• Skeletal, cardiac and smooth muscle cell types, with similar cellular architecture and machinery • Tail-driven locomotion depends on alternating contraction of myotomal muscle
• Fast and slow skeletal muscle ﬁbers • Appendicular muscle bulk is proportionately small
Nervous system and
behavior
• Central nervous system anatomy: fore-, mid- and hind-brain, including diencephalon, telencephalon and cere-
bellum
• Telencephalon has only a rudimentary cortex
• Peripheral nervous system has motor and sensory components • Fish-speciﬁc sensory organs, such as the lateral line
• Enteric and autonomic nervous systems • Fish behaviors and cognitive function are simpliﬁed compared with human behavior
• Specialized sensory organs, eye, olfactory system and vestibular system, are well conserved • Signiﬁcant difference in population of dopaminergic neurons (telencephalic vs midbrain)
• Complex behaviors and integrated neural function: memory, conditioned responses and social behaviors (for
example, schooling)
• Some immediate early genes and neuropeptides not conserved in zebraﬁsh
Hematopoietic and
lymphoid/immune
systems
• Multiple hematopoietic cell types: erythrocytes, myeloid cells (neutrophils, eosinophils, monocytes and
macrophages), T- and B-lymphocytes
• Erythrocytes are nucleated
• Coagulation cascade for hemostasis • Possess thrombocytes rather than platelets
• Innate and adaptive humoral and cellular immunity • Kidney interstitium is the hematopoietic site
Cardiovascular system • Multi-chamber heart with an atrium and ventricle •Has left–right distinctions in cardiac anatomy, but does not have separate left–right
circulations, that is, the heart has only two chambers
• Circulation within arteries and veins •So far no evidence for secondary heart ﬁeld derivatives
• Separate lymphatic circulation • Lymph nodes have not been described
• Cardiac differentiation occurs through similar signaling pathways (eg, nkx2.5, bmp2b) • Embryos are not dependent on functioning CV system for larval development
• Similar electrical properties and conduction patterns (SA node, slow atrial conductance, AV node, fast ventricular
conductance)
• Atria and ventricles express different myosin heavy chains during development (human
hearts only later differentiate between atrial and ventricular mhc)
• Heart has high regenerative capacity, even in adult animals
Respiratory system • Cellular gas exchange • Respiration occurs in gills, not lungs
• Oxygenation is dependent on circulation and hemoglobin carriage • No pulmonary circulation
• Endoderm-derived swim bladder (functioning as a variable buoyancy device), which corre-
sponds embryologically but not functionally to the lungs
Gastrointestinal system • Major organs: liver, exocrine and endocrine pancreas, gall bladder • Lack an acidiﬁed digestive organ
• Zonal specializations along the length of the absorptive alimentary tract • Have an intestinal bulb rather than stomach
• Immune cells in lamina propria • Intestinal Paneth cell not present
Renal and urinary systems • Glomerular anatomy and function • Filtration occurs in anterior and posterior kidneys
• Mesonephric rather than metanephric adult kidney
• No bladder or prostate gland
• No structure in zebraﬁsh homologous to descending or ascending thin limb of nephron in
mammals
Reproductive system • Molecular and embryological biology of germ-cell development • No sex chromosomes
• Cellular anatomy of germ-cell organs, the testis and ovary • Mechanism of sex determination is uncertain
• Fertilization is ex vivo (no uterus or the related internal female reproductive organs)
• Oocytes are surrounded by a chorion, not the zona pellucida, which must be penetrated by
sperm
• Non-lactating; no breast equivalent
Endocrine system • Most endocrine systems represented, including hypothalamic/ hypophyseal axis (glucocorticoids, growth
hormone, thyroid hormone, prolactin), parathyroid hormone, insulin and rennin
• Differences in anatomical distribution of glands, for example, discrete parathyroid glands do
not seem to be present
• Prolactin has a primary role in osmoregulation
Skin and appendages • Ectodermal derivative • Structures unique to ﬁsh that are specialized for the aquatic environment (including, elasmoid
scales, mucous cells)
• Pigmentation pattern is due to neural-crest-derived pigment cells including melanocytes • Lack appendages (hair follicles, sebaceous glands)
• Additional pigment cell types: xanthophores and iridophores
Table adapted from Lieschke and Currie 2007. Nat Rev Genet. 8: 353–367.
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zebraﬁsh publications (www.zﬁn.org and [21]).3. Forward genetics: advances in vertebrate developmental biology
Initial forays in zebraﬁsh research predated the precise knowledge
of gene content or location within the zebraﬁsh genome, and were not
necessarily motivated by targeted questions of human pathology. Rath-
er, most forward screens were conducted to understand vertebrate em-
bryonic development by 1) introducing random mutations throughout
the genome; 2) conducting an informative breeding scheme to generate
progeny with homozygous recessive mutations; 3) evaluating animals
for a measurable phenotypic readout; and 4) identifying the mutation
and gene underscoring the phenotype. Used widely across multiple
model organisms, the application of this traditionally laborious strategy
in zebraﬁsh has been reviewed extensively elsewhere [22].
The ﬁrst zebraﬁsh screens were reported in the 1980s and involved
the application of gamma rays to induce recessive lethal mutations.
However, this approach resulted in signiﬁcant chromosomal breaks
that rendered mapping to a single locus difﬁcult [23,24]. Alkylating
agents, primarily N-ethyl-N-nitrosourea (ENU), replaced gamma rays
as an effective mutagen and application resulted in discrete genomic
mutagenesis in zebraﬁsh germ cells that could be mapped to a single
gene (approximately one mutant per genome evaluated) [25,26]. This
discovery led to large-scale efforts by labs in Tübingen and Boston to
apply ENU screening to zebraﬁsh. Within two years, their combined ef-
forts led to the characterization of ~4000 embryonic lethal phenotypes;
these include gastrulation [27,28]; somitogenesis [29]; brain [30–32];
cardiovascular [33]; and craniofacial development mutants [34–36].
Although forward genetic screens in zebraﬁsh contributed signiﬁ-
cantly to the fundamental understanding of early embryonic develop-
ment, the impact on such ﬁndings to inherited disease in humans has
been sporadic. This modest connection can be attributed to four main
reasons. First, such screens are unable to capture alleles that confer a
dominant negative (antagonizes the wild-type protein function) or
gain of function (mutation confers a protein function different from
that of wild-type protein) effect. Second, phenotypes must have a mea-
surable phenotypic readout in early embryonic or larval stages, decreas-
ing the possibility of detecting adult-onset or degenerative phenotypes.
Third, although such screens were able to uncover discrete gene func-
tions, the odds of generating precisely the same allele by ENU as has
been seen in a patient is remote. Finally, this approach is confounded
further by the fact that the zebraﬁsh genome underwent a teleost spe-
ciﬁc duplication [17–19]. Among the genes for which there is an identi-
ﬁable human ortholog, 47% have a one-to-one orthologous relationship
with a human counterpart, while the remainder of zebraﬁsh genes have
complicated one-to-many or many-to-one orthology in comparison to
the human gene [20]. As a result, duplicated gene function may either
be a) retained in both copies making them functionally redundant;
b) lost in one of the two copies wherein it becomes a pseudogene; or
c) a novel and divergent gene function is acquired by one of the two
copies. Therefore, mutations in only one of two functionally redundant
orthologs might not display a phenotype. Nonetheless, ENU mutants
have been successful in drawing anatomical correlates for genes impli-
cated in recessive human disorders that cause anatomical birth defects.
For instance, the craniofacial mutant crusherm299 is caused by a non-
sense mutation in sec23a [37]; at the same time as this discovery,
SEC23Amutations in humans were shown to cause a clinically relevant
craniofacial dysmorphology, cranio-lenticulo-sutural dysplasia, bolster-
ing the evidence of causality in both species [38]. Importantly, the
recent application of WGS [39], WES [40], and improved mapping
strategies [41] to zebraﬁsh ENU mutants has enabled the rapid and
cost-effective identiﬁcation of mutations, justifying the continued use
of forward genetics to assist with assigning causality in human genetic
disease.4. Reverse genetics: from candidate causal gene to physiologically
relevant animal model
Forward genetic screening involves the unbiased examination of
phenotypes resulting frommutations in the zebraﬁsh genome. Howev-
er, the randomness of this approach is hampered by the inability to spe-
ciﬁcally target every coding gene and/or speciﬁc mutations implicated
in human pathology. To circumvent this problem, the precise targeting
of candidate genes and alleles can be achieved through severalmethods
that have been developed over the past ~15 years.
First, transient gene manipulation can be achieved through the in-
jection of either morpholino (MO) antisense oligonucleotides (suppres-
sion) or capped in vitro transcribed mRNA (ectopic expression) into
zebraﬁsh embryos. MOs are stable molecules that consist of a large,
nonribose morpholine backbonewith the four DNA bases pairing stably
withmRNA at either the translation start site (to disrupt protein synthe-
sis) or at intron–exon boundaries (to disrupt mRNA splicing) [42]. The
use of MOs to confer effective gene knockdown was ﬁrst shown in
zebraﬁsh in 2000; Nasevicius and Ekker recapitulated the developmen-
tal phenotypes of ﬁve different embryonic lethal mutants and also de-
veloped models of the human genetic disorders hepatoerythropoietic
porphyria and holoprosencephaly through the suppression of urod
and shh, respectively [43]. Since this report, MOs have been used broad-
ly to study vertebrate development and disease; co-injection of MO and
orthologous mRNA has been employed for the systematic functional
testing of alleles identiﬁed in humans, offering a powerful approach
for analysis of variant pathogenicity and direction of effect [44]. Still,
this methodology does have notable drawbacks: 1) MO efﬁcacy is limit-
ed to ~3–5 days [43], and similarly, the presence of mRNA is limited to
the same embryonic timeframe; 2) with few exceptions [45], injected
MOs and mRNAs do not confer spatial or temporal speciﬁc activity;
and 3) MOs can give rise to spurious phenotypes resulting from off-
target effects [46]. Even so, the use of thismethodologywithin the appro-
priate developmental stage, and with the appropriate experimental con-
trols a) targeting with a splice-blocking MO to demonstrate incorrectly
spliced RNA; b) speciﬁc rescue of MO phenotypes with orthologous
wild-typemRNA; c) demonstration of a similar phenotype withmultiple
MOs targeting the samegene; or d) comparisonwith amutantwhenpos-
sible, and if appropriate [46] can allow for the correct interpretation of
MO phenotypes to establish relevance to human genetic disease through
the recapitulation of loss-of-function or dominant negative effects.
Second, it is possible to readily obtain germ line zebraﬁsh mutants
for a gene of interest; this avoids the phenotypic variability associated
withMOs, and allows the observation of phenotypes beyondearly larval
stages. Targeting Induced Local Lesions in Genomes (TILLING) was the
ﬁrst reverse genetic approach to produce germ line mutations in a
gene of interest. Similar to forward screens, TILLING involves ENUmuta-
genesis of adult male zebraﬁsh and generation of F1 families. Sperm
fromF1males is then cryopreservedwhile genomic lesions are screened
in target genes, typically in early exons or near exonic regions encoding
critical protein domains, through PCR amplicon screening [47]. The
completion of the zebraﬁsh genome coupled to next-generation se-
quencing has increased signiﬁcantly the throughput of the screening
aspect of this strategy. TILLING mutants have been identiﬁed for N38%
of all known zebraﬁsh protein coding genes (http://www.sanger.ac.
uk/Projects/D_rerio/zmp and [48]); this corresponds to ~60% of
orthologous genes associated with a human phenotype in the Online
Mendelian Inheritance in Man (OMIM; http://www.omim.org) data-
base. The ongoing TILLING efforts hope to generate a comprehensive
resource of putative null or hypomorphic models of human genetic
disease, however, it is critical to be cognizant of the possibility that
ENU may introduce multiple lesions in the genome. Ideally, multiple
mutants with different alleles in the same gene should be phenotyp-
ically characterized to ensure that the pathology is speciﬁc. The same
guidelines are true for retrovirus [49] or transposon [50] insertional
mutants used in similar reverse genetics approaches.
Table 3
Comparison of different reverse genetics approaches.
Methodology Class Speciﬁcity (targeting
sequence)
Off target
effects
Technology adoption
time and costs
Ongoing time
and cost
Somatic DNA cutting efﬁciency Germline efﬁcacy
Morpholinos Morpholino oligo 25 nt Low Low Low n/a n/a
ZFNs Protein-DNA 18+ bp (pair) Low High Moderate Low (~2%) Low
TALENs Protein-DNA 30+ bp (pair) Ultra low Moderate Low Moderate to high (~20 to ~50%) Moderate to high
CRISPR-Cas9 RNA-DNA 12+ bp Ultra low Low Low Moderate to high (~30% to ~60%) Moderate to high
Table adapted from Blackburn et al. 2013 Zebraﬁsh. 10: 116–118.
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proaches have recently expanded the utility of the zebraﬁsh by enabling
precise and germ line transmittable gene targeting that does not require
excessive downstream screening to identify mutations (see ref [14] in
this issue for a detailed review of genome editing endonucleases).
First, zinc ﬁnger nucleases (ZFN) utilize a zinc ﬁnger array to enable tar-
get sequence speciﬁcity (typically the early exon of a gene), and a FokI
endonuclease to guide cleavage and subsequent repair at the target
site [51]; this was ﬁrst utilized to target the gol locus (mutation of
which results in absence of pigment), ntl (a regulator of early embryo-
genesis), and kdr (vascular endothelial growth factor-2 receptor), as
visible proof-of-principle phenotypes [52,53]. Second, transcription
activator-like TAL effector nucleases (TALEN) have similarly been opti-
mized to achieve locus-speciﬁc genome editing and have been shown
to achieve greater speciﬁcity of and alteration of target sequences than
ZFNs [54]. A third, more recent advancement in zebraﬁsh genome
editing technology involves clustered, regularly interspaced, short pal-
indromic repeats (CRISPR), bacterial type II systems that guide RNAs
to direct site-speciﬁc DNA cleavage by the Cas9 endonuclease [55].
Each of ZFN, TALEN, and CRISPR technologies have expanded themolec-
ular toolkit of the zebraﬁsh (for comparisons, see Table 3), accelerating
studies of vertebrate development and improving our understanding of
analogous phenotypes to humandisease. For example, CRISPR/Cas9was
used to edit the gata5 locus [56], andmutant embryos displayed a cardia
biﬁda phenotype mimicking both the fautm236a zebraﬁsh mutant [57],
and also humans with congenital heart defects [58–60]. However,
there is currently a relative paucity of reports in which human-driven
WES/WGS studies have been followed with the generation of such sta-
ble mutants; this is largely due to the relative newness of the technolo-
gy, and/or the amount of time and labor still required to generate and
characterizemutants; we anticipate the landscape of the ﬁeld to change
rapidly in the coming months and years.5. Humanizing the zebraﬁsh to studymutations detected in humans
Taken together, the zebraﬁsh exempliﬁes a tractable and physiolog-
ically relevant tool to model genetic variation in humans. Each of theFig. 1. Zebraﬁshmodels of human genetic disease.A.Mutations in pontocerebellar hypoplasia ar
phenotypes observed in patients and demonstrate thatmissensemutations are functional null v
ages (A5–A8; bottom row); right panel, whole-mount in situ hybridization in splice blocking M
onstrated diminished expression of dorsal hindbrain progenitor-speciﬁc marker atoh1a and ce
2012. Nat Genet. 44: 704–708.B. Congenital abnormalities of the kidney and urinary tract are ca
(Panel B1, kidneys outlined bydashed lines), bilateral hydronephrosis (Panel B2, arrows) caused
kidney (Panel B3, arrow) caused by ureteropelvic junction obstruction. The intravenous pyelo
induced knockdown of dstyk embryos, live lateral images show absence of the patent prone
369: 621–629.C. Adult-onset limb-girdle muscular dystrophy is caused by dominant negative
Z-disks (arrows; left) and autophagic pathology (right) in LGMD1D; C2–C10, lateral views of ze
staining of slow myosin heavy chain display myoﬁber abnormalities (arrows). Images reprodu
protective effect on SMN1 deletion to rescue motor neuron defects in spinal muscular atrophy
(black) SMN1-deleted siblings; D2, lateral view of zebraﬁsh embryos injected with control MO,
tibody at 36 hours post fertilization and show rescue of smnMOwith PLS3 RNA. Images reprodu
multisystemic phenotypes of the 8q24.3 copy number variant. E1, Photographs of ﬁve individua
dorsal views of control and scrib or puf60aMO-injected embryos at 5 dpf show head size and c
2013. Am J Hum Genet. 93: 798–811. LOF, loss-of-function; DN, dominant negative.forward and reverse genetics tools have limitations, and in particular,
place signiﬁcant emphasis toward the study of loss-of-function effects
of single genes potentially making them an overly simplistic model to
investigate oligogenic or even complex traits. In a growing number of
instances, however, it has been possible to balance experimental tracta-
bility, speciﬁcity, and cross-species phenotypic similarity to establish:
1) physiological relevance of a gene to a human clinical phenotype;
2) allele pathogenicity; and 3) direction of allele effect for a vast array
of human genetic disorders with diverse models of inheritance, pheno-
types, and ages of onset.5.1. Recessive disease
Disorders that segregate under a recessive mode of inheritance, es-
pecially congenital or pediatric-onset disorders with an abnormality in
a structure with an anatomical counterpart in the developing zebraﬁsh,
have achieved widespread use toward demonstrating physiological rel-
evance. This often represents the extent of functional data presented in
instances when the human mutations have an unambiguous loss-of-
function effect on the protein (nonsense, frameshift, or splice-site).
For instance, causal mutations identiﬁed in primary ciliary dyskinesia
(PCD) are almost exclusively null changes, and transient MO-based
studies in zebraﬁsh have shown that proteins of a priori unknown func-
tion including CCDC39, ARMC4, and ZMYND10 give rise to left-right
asymmetry defects phenotypes found in humans [61–63]. In other
recessive disorders, such as pontocerebellar hypoplasia (PCH), the
zebraﬁsh has assisted in establishing clinical relevance and allele patho-
genicity (Fig. 1A). Wan et al. identiﬁed nonsynonymous changes in
EXOSC3, encoding exosome component 3, followingWES of four affect-
ed siblings; MO-induced suppression resulted in phenotypes that were
relevant to the human clinical features of microcephaly and reduced
motility in exosc3morphants. Additionally, in vivo complementation of
exosc3MOphenotypeswith either zebraﬁsh or humanmRNAharboring
the missense mutations found in patients failed to rescue the pheno-
type, indicating that these were loss-of-function alleles [64]. Even so,
transient in vivo complementation assays are not applicable to every
gene. Human genes with an open reading frame (ORF) larger thane caused by EXOSC3 and in vivo complementation studies in zebraﬁsh recapitulate the brain
ariants. Left panel, neuroimaging of affected individuals (A1–A4; top row) and control im-
O-injected embryos in lateral view (A9; inset – dorsal view, with rostral to the left) dem-
rebellar-speciﬁc marker pvalb7 (A10; quantiﬁcation). Images reproduced fromWan et al.
used by haploinsufﬁciency of DSTYK. Left, panels B1–B3, with hypoplasia of the left kidney
by ureteropelvic junction obstruction detected at birth, and hydronephrosis only of the left
gram in Panel B4 shows blunting of fornices on the right side (white arrow); right, MO-
phric duct opening (arrows). Images reproduced from Sanna-Cherchi et al. 2013. NEJM.
mutations in DNAJB6. C1, Transmission electron microscopy showed early disruption of
braﬁsh embryos 2 days post fertilization subjected to whole-mount immunoﬂuorescence
ced from Sarparanta et al. 2012. Nat Genet. 44: 450–455.D. PLS3 overexpression exerts a
(SMA). D1, pedigrees of SMA-discordant families showing unaffected (gray) and affected
smnMO, PLS3 RNA, and smnMO+ PLS3 RNA. Motor axons were visualized with znp1 an-
ced fromOprea et al. 2008. Science. 320: 524–527.E. SCRIB and PUF60 suppression drive the
ls with the 8q23.4 CNV show craniofacial abnormalities andmicrocephaly; E2, Lateral and
raniofacial defects observed in affected individuals. Images reproduced from Daubert et al.
1965E.E. Davis et al. / Biochimica et Biophysica Acta 1842 (2014) 1960–1970~6 kb are challenging to transcribe in vitro, likely explaining why
large genes such as NBEAL2, encoding neurobeachin-like 2, the
novel genetic cause for gray platelet syndrome (ORF of 8.2 kb),was shown to cause a relevant thrombocytopenia phenotype in
zebraﬁsh morphants, but the missense mutations identiﬁed in
patients were not tested [65].
1966 E.E. Davis et al. / Biochimica et Biophysica Acta 1842 (2014) 1960–19705.2. Dominant disorders
In contrast to recessive disorders, inwhich the allele effect is typically
loss-of-function, traits that segregate under an autosomal dominant in-
heritance pattern are the result of either a haploinsufﬁciency, dominant
negative, or gain-of-function mechanism. For some dominant pediatric-
onset disorders, the genetic evidence of a heterozygous null variant
segregating in a large pedigree with fully penetrant disease is sufﬁcient
to suggest that the direction of allele effect is haploinsufﬁciency,
and these predictions have been conﬁrmed in zebraﬁsh through
MO-induced gene suppression. For example, dilated cardiomyopathy
is caused by nonsense, splice-site or missense mutations in the gene
encoding heat shockprotein co-chaperone BCL2-associated athanogene
3 (BAG3) and gene suppression results in similar cardiac phenotypes in
zebraﬁsh embryos [66]. Similarly, congenital abnormalities of the kid-
ney and the urinary tract (CAKUT) associated with a loss-of-function
splice sitemutation segregating in a dominant pedigree were identiﬁed
in the dual serine-threonine kinase encoded by DSTYK (Fig. 1B); the
human phenotypes were recapitulated in dstyk morphant embryos
[67]. Transient experiments in zebraﬁsh embryos can also determine al-
lele pathogenicity and capture a dominant negative direction of effect
that is isoform-speciﬁc. This is exempliﬁed by the transient functional
studies of missensemutations in the co-chaperone protein, DNAJB6, as-
sociated recently with adult-onset limb girdle muscular dystrophy
(Fig. 1C) [68]. Co-injection of mutant DNAJB6 mRNA in the presence
of equivalent amounts of wild-type transcript resulted in myoﬁber de-
fects in zebraﬁsh embryos; injection of increasing amounts wild-type
mRNA with a ﬁxed concentration of mutant resulted in a phenotypic
rescue, indicating the dominant toxicity of the mutant alleles. Given
the nature of these mutations (deleterious in heterozygosity), the use
of zebraﬁsh for dissecting dominant disorders will likely remain restrict-
ed to transient MO- and mRNA-based studies until the development of
more sophisticated conditional gene suppression/expression techniques
in zebraﬁsh.
5.3. De novo variants
Variants that arise de novo as a product of either germlinemosaicism
or early developmental DNA replication errors are signiﬁcant contribu-
tors to the human mutational burden [69]. Similar to variants that
underscore autosomal dominant disorders, de novo changes may give
rise to clinical phenotypes produced from falling below a gene dosage
threshold, dominant negative effects, or acquisition of a novel function.
As such, an unbiased approach toward dissecting the direction of de
novo allele effect is critical once physiological relevance has been deter-
mined. For instance, transient approaches have been carried out in
zebraﬁsh to investigate de novo missense mutations in CACNA1C,
encoding the voltage-gated calcium channel Cav1.2, in the pathophysi-
ology of Timothy syndrome (TS), a pediatric disorder characterized by
cardiac arrhythmias, syndactyly, and craniofacial abnormalities. Ectopic
expression of mutant mRNA and suppression of cacna1c in zebraﬁsh
embryos not only revealed that the mutation confers a gain-of-
function effect, but also demonstrated a novel role for Cav1.2 in the
non-excitable cells of the developing jaw [70].
5.3.1. CNVs
Frequently arising de novo, copy number variants (CNVs) likewise
represent a signiﬁcant molecular basis for human genetic disease [71].
These variations in genomic structure can range in size from a few
thousand to millions of base pairs, are not identiﬁable by conventional
chromosomal banding, and can encompass from one to hundreds of
genes [72]. Although genotype–phenotype correlations among affected
individuals with overlapping CNVs can assist in narrowing speciﬁc ge-
netic drivers, CNVs have been historically intractable to functional inter-
pretation in animal models, with sparse reports of human CNVs being
modeled in the mouse [73]. Zebraﬁsh models have emerged recentlyas powerful tools to dissect both recurrent and non-recurrent CNVs.
First, systematic zebraﬁsh modeling of the 29 genes in the recurrent re-
ciprocal 16p11.2 duplication/deletion CNV – associated with a range of
neurocognitive defects – found the main driver of the neuroanatomical
phenotypes to be KCTD13, causing mirrored macro- and microcephaly
upon suppression or overexpression in zebraﬁsh, respectively [74].
Second, MO-induced suppression of three genes in the 8q24.3 non-
recurrent deletion CNV in zebraﬁsh embryos revealed that the planar
cell polarity effector SCRIB, and the splicing factor PUF60 could be linked
to distinct aspects of the renal, short stature, coloboma, and cardiac phe-
notypes observed in ﬁve individualswith overlappingmicrodeletions at
this locus (Fig. 1E) [75].
5.4. Second-site modiﬁers
The demonstration of second-site phenotype modiﬁcation in pri-
marily recessive human genetic disease has been fuelled by the use of
in vivo assays in zebraﬁsh. The ciliopathies, disorders underscored by
dysfunction of the primary cilium, have been causally linked with over
50 different loci, can give rise to a constellation of human phenotypes,
and have been an ideal system to study epistasis [76]. The recent dissec-
tion of the genetic architecture of Bardet–Biedl syndrome (BBS), a
ciliopathy hallmarked by retinal degeneration, obesity, postaxial poly-
dactyly, renal abnormalities, and intellectual disability, 1) informed
the pathogenic potential of missense BBS alleles contributing to the
disorder (null, hypomorphic, or dominant negative); 2) revealed the
surprising contribution of dominant negative alleles in oligogenic pedi-
grees with BBS; and 3) provided sensitivity (98%) and speciﬁcity (82%)
metrics for the zebraﬁsh in vivo complementation assay to predict allele
pathogenicity [77]. Transient zebraﬁsh in vivo complementation assays
have similarly been used to identify RPGRIP1L A229T as a modulator
of retinal endophenotypes [78], RET as a modiﬁer of Hirschsprung phe-
notypes in BBS [79], and TTC21B as a frequent contributor tomutational
load in ciliopathies [80]. Second-site modiﬁcation phenomena are not
unique to the ciliopathies; for example, overexpression of plastin 3
(PLS3) to mimic the gene expression in unaffected individuals,
improved the axon length and growth defects associated with SMN1
deletion in spinal muscular atrophy (SMA). The interaction of these
two genes was shown, in part, through modeling of SMA genotype
and phenotype correlates in zebraﬁsh embryos (Fig. 1D) [81].
5.5. Complex traits
Genome wide association studies (GWAS) alone have been ham-
pered by an inability to connect risk association to genes and underlying
mechanism. However, the zebraﬁsh has emerged as a tool to dissect
genes at or near loci that confer signiﬁcant risk for the complex trait
under investigation. Rare alleles in GWAS hits have beenmore straight-
forward to dissect, since the strategy has been similar to that of Mende-
lian traits. For example, a combination of in vitro analysis of enzyme
stability and secretion and vascular integrity in the retina in zebraﬁsh
embryos demonstrated a functional role for a rare allele in the gene
encoding complement factor I (CFI), thus providing direct evidence for
a loss of function role of CFI in AMD [82]. Zebraﬁsh have also been
used in the absence of candidate coding changes in GWAS-identiﬁed
loci. In one example, Liu et al. assessed the physiological relevance of
candidate genes identiﬁed from a GWAS of chronic kidney disease
among African Americans populations; these efforts identiﬁed KCNQ1
as a functionally relevant candidate due to the glomerular ﬁltration de-
fects observed in kcnq1morphants [83]. Similarly, functional validation
of loci associated with platelet count in cohorts of European ancestry
yielded eleven novel genes implicated in D. rerio blood cell formation
[84]. Although numerous questions remain regarding the combinatorial
effects of GWAS hits, their mechanistic basis for conferring risk, and the
physiological relevance of signiﬁcantly associated sites, both coding and
1967E.E. Davis et al. / Biochimica et Biophysica Acta 1842 (2014) 1960–1970non-coding, the zebraﬁsh offers a tractable tool to begin to dissect
existing GWAS data.
6. Adult onset disease
The majority of zebraﬁsh models discussed so far have been used to
understand the role of genes and alleles in pediatric and congenital dis-
orders, in large part because transientMOandmRNAanalysis is possible
only during development. Nonetheless, given the correct tools and ap-
propriate assays, this model organism is also useful for the study of
adult onset disorders. AMD was one example described above, the util-
ity of the model being extracted from the ability to model vascular in-
tegrity in zebraﬁsh embryos, a phenotype relevant to AMD pathology.
There are numerous other examples as well. In particular, phenotypic
proxies of human neurodegenerative diseases such as schizophrenia,
Huntington, Parkinson, andAlzheimer disease, have been used to exam-
ine the role various genes in these diseases (reviewed extensively in
[85] and [86]), although in almost all cases these studies involved genet-
ic mutants and/or stable transgenes. In one example, stable transgenic
zebraﬁsh expressing human 4-repeat Tau showed Tau accumulation
within neuronal cell bodies axons in neurons throughout the adult
brain, resembling neuroﬁbrillary tangles [87]. Some defects, such as be-
havioral phenotypes, are not immediately observable through anatomic
or histological methods, making it necessary to employ more sensitive
methods of analysis. To this extent, assays for memory and learning im-
pairment [88] and conditioned avoidance [89] allow for quantiﬁable
testing of subtle phenotypes in adult ﬁsh.
7. Conclusion: the road ahead
In the study of humangenetics, animalmodels have provided insight
into the genetics and pathophysiology. The efﬁcacy of amodel organism
always hinges on whether that organismmodels appropriately the tar-
get pathology of humans and whether the experiments necessary to
provide burden of proof are tractable and not cost-prohibitive. In the
context of human and medical genomics, we anticipate that the entire
spectrum of model organisms will continue to be used. Nonetheless, it
is clear that models such as zebraﬁsh and possibly other similar organ-
isms, such asMedaka or Xenopus that offer transparency, low cost and
the ability to manipulate their genome efﬁciently will gain a prominent
role as the community strives tomodel thousands of candidate disease-
associated genes and alleles.
A key requirement toward thewidespread use of the zebraﬁsh to de-
termine pathogenicity of alleles identiﬁed byWES/WGSmoving forward
will be to a) improve throughput of physiologically-relevant models of
human disease (through the rapid generation of in vivo complementa-
tion assays); and b) automated phenotyping and image analysis. While
MOs may still be a tractable option for the evaluation of early develop-
mental phenotypes, the recent ability to generate knock-in mutants
[90], conditional zebraﬁsh mutants [91], and multiplexed mutants [92]
holds great promise toward accelerating disease modeling throughput.
Equally as important, some platforms for high throughput phenotypic
screening of zebraﬁsh larvae have been developed recently [93]. For ex-
ample, one system captures hundreds of three-dimensional morpholog-
ical featureswith speed and accuracy, clustering quantitative phenotypic
signatures so that multiple phenotypes can be detected and classiﬁed si-
multaneously. Nonetheless, this system is limited to bright ﬁeld images,
renderingmarker analysis (by RNA in situ or antibody staining) difﬁcult.
Given that embryo phenotyping represents the most signiﬁcant bottle-
neck in scaling the use of zebraﬁsh in human genomics, there is an
acute need to develop additional transgenic reporter lines to assist
with visualization of cellular and anatomical structures of interest [94],
as well as imaging and embryo manipulation technologies further.
It is also important to note that zebraﬁsh analysis, like all other genetic
and molecular biology tools, has its limitations. MO studies can some-
times generate conﬂicting data, especially in the context of earlydevelopmental phenotypes that aremost sensitive to toxic effects. Rescue
studies and a minimum of two MOs per gene tested, when possible, are
essential to validate ﬁndings. Similarly, multiple independent lines from
genome editing experiments will need to be studied to ensure that the
phenotypes observed are driven by the engineered mutation, not an off-
site introduced allele. Moreover, not all human genes and alleles are
modelable; some 25–30% of the human transcriptome is not present in
zebraﬁsh,while other genes can be difﬁcult tomodel because of divergent
functions or extreme dosage sensitivity (especially transcription factors)
rendering them experimentally difﬁcult. Further, for some disorders
(e.g. pulmonary ﬁbrosis) there cannot be a credible phenotypic surrogate
and distant surrogates might lead to incorrect conclusions. Finally, most
zebraﬁsh studies to date have focused on coding variation; modeling
non-coding variation is signiﬁcantly more taxing, yet remains important,
not least because regulatory regions are likely to be enriched for alleles
that drive GWAS signals [95]. This work is possible, once we recognize
that evolutionary constraints might render some data uninterpretable.
For example, testing multiple sequences located within a 50 kb block of
the regulatory domain of IRX3 (certain variants of which are associated
with obesity in humans) resulted in transgenic zebraﬁsh with expression
in pancreas [96]; knockdown of irx3 in zebraﬁsh reduced the number of
pancreatic beta-cells. However, given current designs, it will be difﬁcult
to execute such experiments at the throughout required to address the
needs of the human genetics community.
Despite these limitations, modeling human variation in zebraﬁsh
embryos has been a signiﬁcant contributor toward dissecting the
causality of genes and alleles in human genetic disorders. Moreover,
the development of human disease models will serve as a platform for
the discovery of novel therapeutic paradigms by employing high-
throughput small molecule screening approaches (reviewed extensive-
ly elsewhere [97,98]). Moving forward, we anticipate that the commu-
nity, through the combinatorial use of all the tools discussed here, will
saturate in the coming years a signiﬁcant fraction of the morbid
human genome. Ultimately, we imagine that such studies will inform
the design of improved computational algorithms, probably through
the training of thousands of human alleles tested in vivo, which will
in turn represent the next inﬂection point in human and medical
genomics.
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